Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2024-0040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Ioannis Katsoulis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Market Access Transformation, Centaur House, Ancells Business Park, Ancells Rd, Fleet, GU51 2UJ, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Decision Making, Medical Oncology. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Health technology assessment (HTA) and payer organizations are often faced with early decision-making in oncology. To design and conduct robust indirect treatment comparisons (ITCs), it is important to better understand HTA and payer decision-maker perceptions of ITCs. Here we aim to describe what individuals with HTA and payer experience see as the acceptability of ITCs for HTA and payer organization coverage and reimbursement decision-making. Materials & methods: This survey included 30 current and former HTA and payer decision-makers from five countries: Australia, France, Germany, the UK (n = 5 each) and the US (n = 10). Main outcomes included the ratings of acceptance of ITCs and the presence of well-defined methodological guidance for ITCs.
Results
ITCs are generally accepted by participants in Australia and the UK but are more likely evaluated on a case-by-case basis in France, Germany and the US. Four of five participants in Germany and the UK, two of five in Australia and one of five in France reported that well-defined and prescribed criteria regarding the use of ITCs were in place.
Conclusion
There is a need for harmonization of methods used to assess ITCs by HTA and payers, especially in the rapidly evolving treatment landscape in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Market Access Transformation, Centaur House, Ancells Business Park, Ancells Rd, Fleet, GU51 2UJ, UK.
- Pfizer, 66 Hudson Boulevard East, New York, NY 10001-2192, USA.
- EMD Serono Research & Development Institute, Inc., 1 Technology Place, Rockland, MA 02370, USA, an affiliate of Merck KGaA.
- Merck Healthcare KGaA, Frankfurter Str. 250, Darmstadt, 64293, Germany.
Zitieren
APA
Katsoulis, I., Graham, A., Thompson, A., Gharibian, N., Pawar, V., Khurana, V., Ferreira, R., Panikar, A., & Kearney, M. (2024). Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0040
Vancouver
Katsoulis I, Graham A, Thompson A, Gharibian N, Pawar V, Khurana V, et al. Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2024-0040
BibTeX
@article{Katsoulis2024,
author = {Katsoulis, Ioannis and Graham, Alex and Thompson, Allison and Gharibian, Norbek and Pawar, Vivek and Khurana, Vivek and Ferreira, Rui and Panikar, Abhishek and Kearney, Mairead},
title = {Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2024-0040}
}
EUVIMED